Research, Industry, Medical and Scientific News

Share

Below you will find news and press releases from industry, government, and academia regarding product developments and medical/scientific research news.

Cavilon skin protectant

Revolutionary Skin Protectant Finally Gives Nurses the Power to Stop, Reverse and Prevent Incontinence Associated Dermatitis

As our aging population grows, nurses are continuing to see more instances of tough-to-manage skin breakdown due to incontinence. Skin damage associated with urine and/or fecal exposure, otherwise known as incontinence associated dermatitis (IAD), is a resource-intensive condition that can be very painful for patients. To help combat this debilitating problem, 3M introduces its revolutionary 3M™ Cavilon™ Advanced Skin Protectant, a high endurance skin protectant designed to stop, reverse and prevent the damaging effects of moderate to severe IAD. The new skin protectant provides clinicians with an easier, more effective way to manage patients with IAD to help improve their quality of life and overall patient experience.  Read more.

Source: Business Wire, February 1, 2017

Eliot Engel

AUA, Urology Care Foundation Applaud Introduction Of Resolution Supporting November As “National Bladder Health Month”

The American Urological Association (AUA) and the Urology Care Foundation, together with the Bladder Health Alliance – a coalition of groups representing physicians, patients and veterans – applauded Congressman Eliot Engel (NY-16) for his introduction of House Resolution 67, a measure supporting the designation of November 2017 as “National Bladder Health Month.”  Read more.

Source: PRNewswire, January 30, 2017

clostridium difficile

Drug May Be New Weapon Against a ‘Superbug’

A newly approved drug may help in the battle against Clostridium difficile — a potentially fatal “superbug” gut infection that has become a scourge in U.S. hospitals. In two clinical trials, researchers found that the drug, called bezlotoxumab (Zinplava), cut the risk of a recurrent C. difficile infection by almost 40 percent. That’s important, because the gut infection commonly comes back after treatment with antibiotics — around 20 percent of the time, according to the U.S. Centers for Disease Control and Prevention. Read more.

HealthDay News, January 25, 2017

product approval

Trulance Approved for Chronic Constipation

Trulance (plecanatide) has been approved by the U.S. Food and Drug Administration to treat persistent constipation of unknown (idiopathic) cause in adults.  Some 42 million people in the United States are affected by constipation, according to the National Institutes of Health. Once-daily Trulance is designed to stimulate the upper gastrointestinal tract to secrete fluid and “support regular bowel function,” the FDA said in a news release. Read more.

Source: HealthDay News, January 20, 2017

Health Canada logo

Axonics Sacral Neuromodulation System Receives Marketing Approval

Axonics Modulation Technologies, Inc. announced today that it received a Homologation d’un instrument médical (medical device approval) for the first rechargeable Sacral Neuromodulation (r-SNM™) System® to treat Overactive Bladder (OAB), Fecal Incontinence and Urinary Retention.  The Health Canada license confirms that the Axonics® product meets all of the Canadian Medical Devices Regulations, Section 36, for Active Implantable Medical Devices and enables Axonics to market its r-SNM System throughout Canada. Read more.

Source: Yahoo! Finance, January 5, 2017

build strength with vaginal weights

Strong Muscles Tied to Lower Risk of Incontinence in Older Women

Women who have more lean muscle mass or better grip strength may be less likely to experience a common type of urinary incontinence, a study suggests.  That’s because strong muscles may help counter what’s known as stress urinary incontinence, which happens when the pelvic floor muscles supporting the bladder are too weak to prevent urine leaks when people do things like cough, sneeze or exercise. Childbirth is a common reason for weak pelvic muscles, and obesity makes the problem worse. Read more.

Source: WHBL, December 15, 2016

operating room

StimGuard Enrolls First Patient in Office-Based Chronic Tibial Nerve OAB Incontinence Stimulation Study Utilizing the World’s Smallest Wireless System

StimGuard, a privately-held, pre-commercial stage medical device company, today announced the initiation and the first patient enrollment in a clinical trial of the world’s first miniature implantable device for the treatment of urgency urinary incontinence resulting from refractory overactive bladder (OAB) syndrome. The StimGuard device utilizes wireless technology and is placed through an introducer device the size of a needle at the tibial nerve to activate the afferent micturition (neural urinary) pathways. The clinical trial of this novel approach will launch this winter. Read more.

Source: Business Wire, December 15, 2016